Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

I n a world where seeking help to manage weight is still frowned upon and deemed as “lazy,” many are turning to common tools ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

OB-GYNs explain how they're using semaglutide and tirzepatide to treat symptoms of PCOS. The meds help treat weight gain, ...

Here’s some of our top analysis to help you make sense of it all. Accountable care organizations and healthcare providers are ...

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...